In a brutal first quarter for Roche, key drugs in the company’s pharmaceutical division fall short of Wall Street ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures. | ...

The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective ...

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...

Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go ...

Travis Smith was a very serious baby. Born completely unable to hear, his mother, Sierra, struggled to see his personality ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Normally on Big Pharma earnings calls, execs are eager to talk up their new launches and tout blockbuster expectations. | In ...

An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...